Opinion|Videos|May 5, 2025
Diagnosis of cGVHD: Challenges & Considerations
Panelists discuss how difficult-to-diagnose cases of chronic graft-vs-host disease (cGVHD) often include pulmonary involvement, gynecological manifestations, and neurological symptoms.
Advertisement
Episodes in this series
Difficult-to-Diagnose Manifestations
The panelists discussed challenging presentations:
- Pulmonary involvement is often insidious, requiring careful monitoring with serial PFTs
- Genital/gynecologic involvement is often underdiagnosed but impacts quality of life significantly
- Neuropathies are difficult to attribute to cGVHD due to multiple potential causes
- Peripheral edema can make assessment of skin thickening/sclerosis challenging
- Serositis (inflammation of tissue lining around heart, lungs, abdomen) is difficult to diagnose and manage
- Immune cytopenias within the cGVHD syndrome can be challenging
Early detection strategies include:
- Serial PFTs (pre-transplant, day 80-90, 6 months, 12 months, 18 months, 2 years)
- Early ophthalmology and dental evaluations
- Patient education about reporting symptoms early
- Regular scheduled follow-ups via telehealth or in-person
Advertisement
Related to this article
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5